|Day's Range||0.1000 - 0.1000|
Acorda Therapeutics, Inc. (ACOR) today announced the launch of the “Do Tell” Your Doctor Tool, a new online questionnaire designed to help people with Parkinson’s (PwPs) and their care partners better identify and articulate their symptoms. OFF periods, or the re-emergence of Parkinson’s symptoms, can be difficult to describe because they differ from person to person, and often from day to day. The “Do Tell” Your Doctor Tool, which can be accessed at LiveWellDoTell.org, offers a visual guide and glossary to help PwPs and their care partners recognize and record their troublesome symptoms, with the intent of fostering better dialogue with their healthcare provider.
Acorda Therapeutics, Inc. (ACOR) will host a conference call and webcast to report its third quarter 2019 update and financial results on Monday, November 4 at 4:30 p.m. ET. The archived webcast will be available in the Investor Relations section of the Acorda website at www.acorda.com. Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders.
The U.S. Supreme Court on Monday declined to hear Acorda Therapeutics Inc's appeal of a lower court ruling that allowed generic versions of its multiple sclerosis treatment Ampyra and caused the drug's sales to plummet. The justices refused to review a September 2018 decision by the U.S. Court of Appeals for the Federal Circuit to cancel Acorda's patents covering Ampyra, a ruling the Ardsley, New York-based company and the pharmaceutical industry portrayed as a threat to innovation and bad for patients. According to Acorda, Ampyra was the first drug approved to improve walking in people with multiple sclerosis, an incurable and potentially disabling disease of the brain and spinal cord that can lead to symptoms including pain, visual impairments and difficulty walking.
Acorda (ACOR) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Menlo (MNLO) completes enrollment in the phase II study evaluating the safety and efficacy of once-daily oral serlopitant for the treatment of CPUO.
Acorda Therapeutics, Inc. (ACOR) announced that Ron Cohen, M.D., Acorda’s President and Chief Executive Officer, will present at the 2019 Cantor Global Healthcare Conference on Friday, October 4 at 11:15AM ET. Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA™ (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa.
Acceleron Pharma's (XLRN) pipeline candidate, ACE-083, fails to translate muscle volume growth into improvements in functional tests in FSHD patients. Acceleron discontinues development.
Acorda Therapeutics, Inc. (ACOR) today announced that it will present data at the International Congress of Parkinson’s Disease and Movement Disorders, taking place September 22-26, 2019 in Nice, France. Acorda and other industry sponsors are members of The Michael J. Fox Foundation Industry Advisory Board and contributed to the design of and provided funding for the “Financial and Social Impact of Parkinson’s Disease Survey.” Results of the survey were also presented at the 5th World Parkinson Congress in June 2019. Acorda will also host a Corporate Therapeutics Symposium, “Rethinking the Approach to Managing OFF Periods,” on Tuesday, September 24 from 12:45 PM to 1:45 PM CEST in the Nice Acropolis Convention Centre.
The FDA grants orphan drug status to Akari's (AKTX) nomacopan for the treatment of bullous pemphigoid, a severe blistering skin condition.
Adaptimmune Therapeutics (ADAP) gets Orphan Drug Designation for SPEAR T-cells targeting MAGE-A4 (ADP-A2M4 program) for the treatment of soft tissue sarcomas.
Horizon (HZNP) announces the FDA has accepted the Biologics License Application (BLA) for teprotumumab, for the treatment of active thyroid eye disease, and granted it Priority Review designation.
Some stocks are best avoided. We really hate to see fellow investors lose their hard-earned money. Imagine if you held...
Acorda's (ACOR) lead MS drug Ampyra is hit by generic rivalry in the United States, which is hurting the company's top line. Parkinson's disease drug Inbrija can be an ideal replacement.
Synlogic (SYBX) discontinues the development of its early-stage pipeline candidate, SYNB1020, for the treatment of hyperammonemia, following disappointing study results.